Abstract
Background: Valproic acid (VPA) as a widely used primary medication in the treatment of epilepsy is associated with reversible or irreversible hepatotoxicity. Long-term VPA therapy is also related to increased risk for the development of non-alcoholic fatty liver disease (NAFLD). In this review, metabolic elimination pathways of VPA in the liver and underlying mechanisms of VPA-induced hepatotoxicity are discussed.
Methods: We searched in PubMed for manuscripts published in English, combining terms such as “Valproic acid”, “hepatotoxicity”, “liver injury”, and “mechanisms”. The data of screened papers were analyzed and summarized.
Results: The formation of VPA reactive metabolites, inhibition of fatty acid β-oxidation, excessive oxidative stress and genetic variants of some enzymes, such as CPS1, POLG, GSTs, SOD2, UGTs and CYPs genes, have been reported to be associated with VPA hepatotoxicity. Furthermore, carnitine supplementation and antioxidants administration proved to be positive treatment strategies for VPA-induced hepatotoxicity.
Conclusion: Therapeutic drug monitoring (TDM) and routine liver biochemistry monitoring during VPA-therapy, as well as genotype screening for certain patients before VPA administration, could improve the safety profile of this antiepileptic drug.
Keywords: Valproic acid, antiepileptic treatment, liver injury, management, glucuronic acid conjugation, β-oxidation, oxidative stress, genetic variants.
[1]
Silva MF, Aires CC, Luis PB, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review. J Inherit Metab Dis 2008; 31(2): 205-16.
[2]
Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev 2003; 9(2): 199-216.
[3]
Paino F, La Noce M, Tirino V, et al. Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells 2014; 32(1): 279-89.
[4]
Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem 2013; 46(15): 1323-38.
[5]
Almario EE, Borlak J, Suzuki A, Chen M. Drug-Induced Liver Injury. BioMed Res Int 2017; 20172461694
[6]
Zeng K, Wang X, Xi Z, Yan Y. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clin Neurol Neurosurg 2010; 112(4): 291-5.
[7]
Perucca E. Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 2002; 16(10): 695-714.
[8]
Luef G, Rauchenzauner M, Waldmann M, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009; 86(1): 42-7.
[9]
Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A. Valproic acid and nonalcoholic fatty liver disease: A possible association? World J Hepatol 2015; 7(9): 1251-7.
[10]
Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 2009; 37(1): 229-36.
[11]
Krishnaswamy S, Hao Q, Al-Rohaimi A, et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 2005; 313(3): 1340-6.
[12]
Chung JY, Cho JY, Yu KS, et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 2008; 83(4): 595-600.
[13]
Luís PB, Ruiter JP, Ofman R, et al. Valproic acid utilizes the isoleucine breakdown pathway for its complete β-oxidation. Biochem Pharmacol 2011; 82(11): 1740-6.
[14]
Li J, Norwood DL, Mao LF, Schulz H. Mitochondrial metabolism of valproic acid. Biochemistry 1991; 30(2): 388-94.
[16]
Aires CC, Ruiter JP, Luís PB, et al. Studies on the extra-mitochondrial CoA -ester formation of valproic and Delta4 -valproic acids. Biochim Biophys Acta 2007; 1771(4): 533-43.
[17]
Silva MF, Ruiter JP, IJlst L, et al. Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites. Anal Biochem 2001; 290(1): 60-7.
[18]
Silva MF, Ruiter JP, Overmars H, et al. Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 2002; 362(Pt 3): 755-60.
[19]
Silva MF, Ijlst L, Allers P, et al. Valproyl-dephosphoCoA: A novel metabolite of valproate formed in vitro in rat liver mitochondria. Drug Metab Dispos 2004; 32(11): 1304-10.
[20]
Katayama H, Watanabe M, Yoshitomi H, et al. Urinary metabolites of valproic acid in epileptic patients. Biol Pharm Bull 1998; 21(3): 304-7.
[21]
Ponchaut S, van Hoof F, Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 1992; 43(11): 2435-42.
[22]
Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997; 283(2): 698-703.
[23]
Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006; 94(2): 261-71.
[24]
Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 2003; 3(6): 335-42.
[25]
Gopaul SV, Farrell K, Abbott FS. Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab Dispos 2000; 28(7): 823-32.
[26]
Kassahun K, Hu P, Grillo MP, Davis MR, Jin L, Baillie TA. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem Biol Interact 1994; 90(3): 253-75.
[27]
Kassahun K, Farrell K, Abbott F. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab Dispos 1991; 19(2): 525-35.
[28]
Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984; 4(6): 1143-52.
[29]
Star K, Edwards IR, Choonara I. Valproic acid and fatalities in children: A review of individual case safety reports in VigiBase. PLoS One 2014; 9(10)e108970
[30]
Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002; 43(Suppl. 3): 53-9.
[31]
Kondo T, Kaneko S, Otani K, et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia 1992; 33(1): 172-7.
[32]
Gopaul S, Farrell K, Abbott F. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 2003; 44(3): 322-8.
[33]
McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300(2): 361-6.
[34]
Bhatt DK, Mehrotra A, Gaedigk A, et al. Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver. Clin Pharmacol Ther 2018.
[35]
Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2013; 23(4): 236-41.
[36]
Price KE, Pearce RE, Garg UC, et al. Effects of valproic acid on organic acid metabolism in children: A metabolic profiling study. Clin Pharmacol Ther 2011; 89(6): 867-74.
[37]
Hooper WD, Franklin ME, Glue P, et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Epilepsia 1996; 37(1): 91-7.
[38]
Bai X, Hong W, Cai P, et al. Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis. Toxicol Appl Pharmacol 2017; 324: 12-25.
[39]
Becker CM, Harris RA. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch Biochem Biophys 1983; 223(2): 381-92.
[40]
Qiliang L, Wenqi S, Hong J. Carnitine deficiency in chinese children with epilepsy on valproate monotherapy. Indian Pediatr 2018; 55(3): 222-4.
[41]
Katayama H, Mizukami K, Yasuda M, Hatae T. Effects of Carnitine on Valproic Acid Pharmacokinetics in Rats. J Pharm Sci 2016; 105(10): 3199-204.
[42]
Aires CC, Ijlst L, Stet F, et al. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol 2010; 79(5): 792-9.
[43]
Luís PB, Ruiter JP, Ijlst L, et al. Role of isovaleryl-CoA dehydrogenase and short branched-chain acyl-CoA dehydrogenase in the metabolism of valproic acid: implications for the branched-chain amino acid oxidation pathway. Drug Metab Dispos 2011; 39(7): 1155-60.
[44]
Abo Alrob O, Lopaschuk GD. Role of CoA and acetyl-CoA in regulating cardiac fatty acid and glucose oxidation. Biochem Soc Trans 2014; 42(4): 1043-51.
[45]
Yao KW, Mao LF, Luo MJ, Schulz H. The relationship between mitochondrial activation and toxicity of some substituted carboxylic acids. Chem Biol Interact 1994; 90(3): 225-34.
[46]
Aires CC, Soveral G, Luís PB, et al. Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes. FEBS Lett 2008; 582(23-24): 3359-66.
[47]
Murphy JV, Marquardt KM, Shug AL. Valproic acid associated abnormalities of carnitine metabolism. Lancet 1985; 1(8432): 820-1.
[48]
Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000; 34(5): 630-8.
[49]
Kulhas Celik I, Tasdemir HA, Ince H, Celik H, Sungur M. Evaluation ofserum free carnitine/acylcarnitine levels and left ventricular systolic functions in children with idiopathic epilepsy receiving valproic acid. Clin Neurol Neurosurg 2018; 170: 106-12.
[50]
Reynolds MF, Sisk EC, Rasgon NL. Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: A review. Curr Med Chem 2007; 14(26): 2799-812.
[51]
Farkas V, Bock I, Cseko J, Sandor A. Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition. Biochem Pharmacol 1996; 52(9): 1429-33.
[52]
Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Crit Care 2005; 9(5): 431-40.
[53]
Jafarian I, Eskandari MR, Mashayekhi V, Ahadpour M, Hosseini MJ. Toxicity of valproic acid in isolated rat liver mitochondria. Toxicol Mech Methods 2013; 23(8): 617-23.
[54]
Kiang TK, Teng XW, Karagiozov S, Surendradoss J, Chang TK, Abbott FS. Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes. Toxicol Sci 2010; 118(2): 501-9.
[55]
Chang TK, Abbott FS. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab Rev 2006; 38(4): 627-39.
[56]
Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci 2005; 86(2): 427-35.
[57]
Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 2005; 86(2): 436-43.
[58]
Pourahmad J, Eskandari MR, Kaghazi A, Shaki F, Shahraki J, Fard JK. A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis. Toxicol In Vitro 2012; 26(4): 545-51.
[59]
Kiang TK, Teng XW, Surendradoss J, Karagiozov S, Abbott FS, Chang TK. Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: Role of biotransformation and temporal relationship with onset of toxicity. Toxicol Appl Pharmacol 2011; 252(3): 318-24.
[60]
Komulainen T, Lodge T, Hinttala R, et al. Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model. Toxicology 2015; 331: 47-56.
[61]
Jin J, Xiong T, Hou X, et al. Role of Nrf2 activation and NF-κB inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice. Food Chem Toxicol 2014; 73: 95-104.
[62]
Luef GJ, Waldmann M, Sturm W, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004; 55(5): 729-32.
[63]
Lee MH, Kim M, Lee BH, et al. Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. Toxicol Appl Pharmacol 2008; 226(3): 271-84.
[64]
Bjorge SM, Baillie TA. Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite, 2-n-propyl-4-pentenoic acid. Biochem Biophys Res Commun 1985; 132(1): 245-52.
[65]
Wang W, Lin R, Zhang J, et al. Involvement of fatty acid metabolism in the hepatotoxicity induced by divalproex sodium. Hum Exp Toxicol 2012; 31(11): 1092-101.
[66]
van Breda SGJ, Claessen SMH, van Herwijnen M, et al. Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology 2018; 393: 160-70.
[67]
Summar ML, Gainer JV, Pretorius M, et al. Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function. Hypertension 2004; 43(2): 186-91.
[68]
Yagi M, Nakamura T, Okizuka Y, et al. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia. Pediatr Int 2010; 52(5): 744-8.
[69]
Sitarz KS, Elliott HR, Karaman BS, Relton C, Chinnery PF, Horvath R. Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts. Mol Genet Metab 2014; 112(1): 57-63.
[70]
Stewart JD, Horvath R, Baruffini E, et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010; 52(5): 1791-6.
[71]
Saneto RP, Lee IC, Koenig MK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010; 19(3): 140-6.
[72]
Hynynen J, Komulainen T, Tukiainen E, et al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl 2014; 20(11): 1402-12.
[73]
Fukushima Y, Seo T, Hashimoto N, Higa Y, Ishitsu T, Nakagawa K. Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum gamma-glutamyltransferase in valproic acid-treated patients. Clin Chim Acta 2008; 389(1-2): 98-102.
[74]
Saruwatari J, Deguchi M, Yoshimori Y, et al. Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases. Epilepsy Res 2012; 99(1-2): 183-6.
[75]
Hung CC, Ho JL, Chang WL, et al. Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics 2011; 12(8): 1107-17.
[76]
Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010; 112(4): 320-3.
[77]
Bűdi T, Tóth K, Nagy A, et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia 2015; 56(6): 849-55.
[78]
DeVivo DC. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2002; 58(3): 507-8.
[79]
Romero-Falcón A, de la Santa-Belda E, García-Contreras R, Varela JM. A case of valproate-associated hepatotoxicity treated with L-carnitine. Eur J Intern Med 2003; 14(5): 338-40.
[80]
Knapp AC, Todesco L, Beier K, et al. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. J Pharmacol Exp Ther 2008; 324(2): 568-75.
[81]
Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: A systematic review of published cases. Ann Pharmacother 2010; 44(7-8): 1287-93.
[82]
Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009; 47(2): 101-11.
[83]
Thurston JH, Hauhart RE. Amelioration of adverse effects of valproic acid on ketogenesis and liver coenzyme A metabolism by cotreatment with pantothenate and carnitine in developing mice: possible clinical significance. Pediatr Res 1992; 31(4 Pt 1): 419-23.
[84]
Felker D, Lynn A, Wang S, Johnson DE. Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. Expert Rev Clin Pharmacol 2014; 7(2): 211-8.
[85]
Nazmy EA, El-Khouly OA, Atef H, Said E. Sulforaphane protects against sodium valproate-induced acute liver injury. Can J Physiol Pharmacol 2017; 95(4): 420-6.
Call for Papers in Thematic Issues
30 July, 2024
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
18 September, 2024
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
29 September, 2024
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
30 June, 2024
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Drug Addiction Mechanisms in the Brain
The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
New Avenues in Drug Discovery and Bioactive Natural Products
Practice and Re-Emergence of Herbal Medicine
Article Metrics
226
22
2
